Company Description
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases.
Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment.
The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus.
It has license agreements with Nationwide Children’s Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH.
The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts. Avenue Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 80 |
| CEO | Manuel Litchman |
Contact Details
Address: 377 Plantation Street, 1st Floor Worcester, Massachusetts 01605 United States | |
| Phone | 781 652 4500 |
| Website | mustangbio.com |
Stock Details
| Ticker Symbol | MBIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001680048 |
| CUSIP Number | 62818Q104 |
| ISIN Number | US62818Q2030 |
| Employer ID | 47-3828760 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Manuel Litchman M.D. | President, Chief Executive Officer, Director and Interim Chief Financial Officer |
| Michael S. Weiss Esq. | Executive Chairman |
| Peter Carney | Controller and Interim Chief Accounting Officer |
| Matthew Wein J.D. | Vice President and General Counsel |
| Debra Manning SPHR | Senior Vice President and Head of Human Resources |
| Lynn E. Bayless M.S. | Vice President and Head of Regulatory Affairs |
| Dr. Bruce Dezube M.D. | Senior Vice President and Head of Clinical Development |
| Greg Furrow M.S. | Chief Quality Officer |
| Richard Bodmer M.S. | Head of CMC Development |
| Robert Sexton M.B.A., M.S. | Vice President and Head of Program and Alliance Leadership |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 6, 2024 | DEF 14A | Other definitive proxy statements |
| Dec 2, 2024 | 424B3 | Prospectus |
| Nov 27, 2024 | EFFECT | Notice of Effectiveness |
| Nov 22, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 15, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |
| Oct 25, 2024 | 8-K | Current Report |
| Sep 13, 2024 | 8-K | Current Report |